SCHEMBL6296556

SCHEMBL6296556

CCCC1=C(C(=O)OCC)C(c2cccc(F)c2F)c2c[nH]nc2N1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR3C2 P08235 1/20 0.41
CACNA1D Q01668 1/20 0.39
MEN1 O00255 4/20 0.39
KMT2A Q03164 4/20 0.39
ALDH1A1 P00352 3/20 0.39
ADORA2A P29274 1/20 0.38
ADORA2B P29275 1/20 0.38
ADORA3 P0DMS8 2/20 0.37
TSHR P16473 2/20 0.37
KDM4E B2RXH2 3/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
CYP2C9 P11712 3/20 0.36
CYP1A2 P05177 2/20 0.36
CYP3A4 P08684 2/20 0.36
CYP2C19 P33261 2/20 0.36
HIF1A Q16665 2/20 0.36
HSD17B10 Q99714 2/20 0.36
MTOR P42345 2/20 0.36
HPGD P15428 1/20 0.36
TP53 P04637 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6292574 0.92 NR3C2 (0.41) NR3C2CACNA1DMEN1KMT2AALDH1A1
SCHEMBL6297228 0.92 MEN1 (0.44) NR3C2CACNA1DMEN1KMT2AALDH1A1
SCHEMBL6292334 0.90 NR3C2 (0.42) NR3C2CACNA1DMEN1KMT2AALDH1A1
SCHEMBL6296991 0.85 NR3C2 (0.45) NR3C2CACNA1DMEN1KMT2AADORA2A
SCHEMBL6292217 0.85 ALOX15 (0.42) NR3C2CACNA1DMEN1KMT2AALDH1A1
SCHEMBL8342908 0.85 NR3C2 (0.41) NR3C2CACNA1DMEN1KMT2AALDH1A1
SCHEMBL6296533 0.85 NR3C2 (0.44) NR3C2CACNA1DMEN1KMT2AALDH1A1
SCHEMBL6293708 0.85 CA1 (0.45) NR3C2CACNA1DMEN1KMT2AADORA2A
SCHEMBL6292579 0.84 CYP2C9 (0.44) NR3C2CACNA1DMEN1KMT2AALDH1A1
SCHEMBL6293728 0.84 CYP2C9 (0.44) NR3C2CACNA1DMEN1KMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6977262-B2 Dihydropyrazolopyridine compounds and pharmaceutical use thereof MITSUBISHI PHARMA CORPORATION (JP) 2005-12-20 US disclosed
US-20040052822-A1 Dihydropyrazolopyridine compounds and pharmaceutical use thereof MITSUBISHI PHARMA CORPORATION (JP) 2004-03-18 US disclosed
EP-1355909-A2 DIHYDROPYRAZOLOPYRIDINE COMPOUNDS AND PHARMACEUTICAL USE THEREOF Mitsubishi Pharma Corporation (JP) 2003-10-29 EP disclosed
WO-2002062795-A2 DIHYDROPYRAZOLOPYRIDINE COMPOUNDS AND PHARMACEUTICAL USE THEREOF MITSUBISHI PHARMA CORPORATION (JP) 2002-08-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040052822-A1 Dihydropyrazolopyridine compounds and pharmaceutical use thereof GSK3B, GSK3A, PYGB NR3C2 2858/4885CACNA1D 271/4885MEN1 3826/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.